Investigation of chromatin remodeling by histone modifier protein in carcinogenesis and progression.

点击翻译按钮获取中文摘要

It is demonstrated that MEK-ERK1/2-Elk-1 pathway leads to EZH2 overexpression. The triple-negative and ERBB2-overexpressing subtypes of breast cancer are known to contain more rapidly proliferating breast cancer cells. The signaling pathway connected to EZH2 overexpression was associated with both aggressive subtypes of breast cancer, showing one of the clinicopathological significance of overexpression of histone modifier protein. The oncogenic role of EZH2, a histone modifier protein that is induced by oncogenic mutant RAS is also defined in pancreatic carcinogenesis, using pancreatic cancers of transgenic rats exogenously expressing human mutant RAS. That is, EZH2 was found to be a real effecter protein in the downstream of the MEK-ERK pathway in pancreatic carcinogenesis.